Clinical Trials for Mesothelioma Patients: Immunotoxin Therapy Disease
Characteristics
Read about the disease characteristics for a current clinical trial being
conducted to study the effects of Immunotoxin Therapy for patients who have been
diagnosed with mesothelioma. Please note: this information is provided by Weitz
& Luxenberg for informational purposes only. At this time, the study is
currently being conducted only in Zurich, Switzerland.
Disease Characteristics: •
Histologically confirmed epithelial pleural mesothelioma not amenable to
potentially curative surgical resection o Unresectable disease, defined as
any 1 of the following: Metastatic disease Patient found at surgery
not to be amenable to resection Not to benefit from surgery due to
extensive local disease or not a surgical candidate due to comorbid medical
conditions as deemed by a qualified oncologist • Measurable disease • No
documented and ongoing CNS involvement with malignant disease (history of CNS
involvement is not an exclusion criterion)
Courtesy of ClinicalTrials.gov,
a service of the U.S. National Institutes of Health
Mesothelioma & Asbestosis Mortalities Across the US: 1979-2001 (c/o EWG)
“We have seen first-hand how asbestos has wreaked havoc on Americans working in naval shipyards, automobile plants, and the construction industry. Most often this is through their employers’ conscious choice for profits over a worker's health.”
-- Joseph Patrick Williams, a trial attorney in the Asbestos Litigation department of Weitz & Luxenberg
Therapy program to treat mesothelioma patients with Immunotoxin